ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 9.27
(1.64%)
CNY 9.27
(1.64%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 393.81 Million CNY | -34.74% |
| 2022 | 603.44 Million CNY | 162.84% |
| 2021 | 229.58 Million CNY | -31.49% |
| 2020 | 335.09 Million CNY | -5.13% |
| 2019 | 353.2 Million CNY | 22.73% |
| 2018 | 287.8 Million CNY | 19.82% |
| 2017 | 240.2 Million CNY | -3.15% |
| 2016 | 248 Million CNY | 36.26% |
| 2015 | 182 Million CNY | 40.0% |
| 2014 | 130 Million CNY | -9.09% |
| 2013 | 143 Million CNY | 84.52% |
| 2012 | 77.5 Million CNY | 93.75% |
| 2011 | 40 Million CNY | -33.33% |
| 2010 | 60 Million CNY | 0.0% |
| 2009 | 60 Million CNY | 50.0% |
| 2008 | 40 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 126.5 Million CNY | -64.0% |
| 2024 Q1 | 417.63 Million CNY | 6.05% |
| 2024 Q2 | 422.14 Million CNY | 1.08% |
| 2023 Q2 | 295.89 Million CNY | -51.16% |
| 2023 Q1 | 605.87 Million CNY | 0.4% |
| 2023 Q4 | 393.81 Million CNY | -3.04% |
| 2023 FY | 393.81 Million CNY | -34.74% |
| 2023 Q3 | 406.16 Million CNY | 37.27% |
| 2022 Q4 | 603.44 Million CNY | 117.83% |
| 2022 FY | 603.44 Million CNY | 162.84% |
| 2022 Q2 | 220.75 Million CNY | -4.03% |
| 2022 Q3 | 277.02 Million CNY | 25.49% |
| 2022 Q1 | 230.02 Million CNY | 0.19% |
| 2021 Q3 | 259.46 Million CNY | -10.54% |
| 2021 Q4 | 229.58 Million CNY | -11.52% |
| 2021 Q2 | 290.03 Million CNY | -6.0% |
| 2021 FY | 229.58 Million CNY | -31.49% |
| 2021 Q1 | 308.56 Million CNY | -7.92% |
| 2020 Q3 | 321.52 Million CNY | -20.5% |
| 2020 Q1 | 408.77 Million CNY | 15.73% |
| 2020 Q2 | 404.44 Million CNY | -1.06% |
| 2020 Q4 | 335.09 Million CNY | 4.22% |
| 2020 FY | 335.09 Million CNY | -5.13% |
| 2019 Q1 | 277.8 Million CNY | -3.47% |
| 2019 FY | 353.2 Million CNY | 22.73% |
| 2019 Q2 | 229.7 Million CNY | -17.31% |
| 2019 Q4 | 353.2 Million CNY | 3.98% |
| 2019 Q3 | 339.7 Million CNY | 47.89% |
| 2018 Q3 | 290.9 Million CNY | 20.26% |
| 2018 FY | 287.8 Million CNY | 19.82% |
| 2018 Q2 | 241.9 Million CNY | 9.38% |
| 2018 Q4 | 287.8 Million CNY | -1.07% |
| 2018 Q1 | 221.16 Million CNY | -7.93% |
| 2017 Q4 | 240.2 Million CNY | -23.87% |
| 2017 FY | 240.2 Million CNY | -3.15% |
| 2017 Q1 | 296.7 Million CNY | 19.64% |
| 2017 Q2 | 290.7 Million CNY | -2.02% |
| 2017 Q3 | 315.5 Million CNY | 8.53% |
| 2016 Q1 | 282 Million CNY | 54.95% |
| 2016 FY | 248 Million CNY | 36.26% |
| 2016 Q4 | 248 Million CNY | 10.22% |
| 2016 Q3 | 225 Million CNY | -20.49% |
| 2016 Q2 | 283 Million CNY | 0.35% |
| 2015 Q2 | 207 Million CNY | 59.23% |
| 2015 Q3 | 82 Million CNY | -60.39% |
| 2015 Q4 | 182 Million CNY | 121.95% |
| 2015 FY | 182 Million CNY | 40.0% |
| 2015 Q1 | 130 Million CNY | 0.0% |
| 2014 Q3 | 85 Million CNY | 0.0% |
| 2014 Q2 | 85 Million CNY | -30.89% |
| 2014 Q1 | 123 Million CNY | -13.99% |
| 2014 FY | 130 Million CNY | -9.09% |
| 2014 Q4 | 130 Million CNY | 52.94% |
| 2013 Q1 | 30 Million CNY | -61.29% |
| 2013 Q3 | 110 Million CNY | 0.0% |
| 2013 Q4 | 143 Million CNY | 30.0% |
| 2013 FY | 143 Million CNY | 84.52% |
| 2013 Q2 | - CNY | -100.0% |
| 2012 Q3 | 77.5 Million CNY | 0.0% |
| 2012 FY | 77.5 Million CNY | 93.75% |
| 2012 Q2 | 77.5 Million CNY | 10.71% |
| 2012 Q1 | 70 Million CNY | 75.0% |
| 2012 Q4 | 77.5 Million CNY | 0.0% |
| 2011 Q4 | 40 Million CNY | 0.0% |
| 2011 Q2 | 60 Million CNY | 0.0% |
| 2011 Q3 | 40 Million CNY | -33.33% |
| 2011 FY | 40 Million CNY | -33.33% |
| 2010 FY | 60 Million CNY | 0.0% |
| 2010 Q4 | 60 Million CNY | 0.0% |
| 2009 FY | 60 Million CNY | 50.0% |
| 2008 FY | 40 Million CNY | 0.0% |